{"id":"placebp","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Alprazolam","action":"Monitor","effect":"Increased sedation"},{"drug":"Cimetidine","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Ciprofloxacin","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Diltiazem","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Erythromycin","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Fluoxetine","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Itraconazole","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Ketoconazole","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Omeprazole","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Rifampin","action":"Monitor","effect":"Decreased levels of Placebo"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels of Placebo"},{"drug":"Verapamil","action":"Monitor","effect":"Increased levels of Placebo"}],"commonSideEffects":[],"contraindications":["Personal or family history of medullary thyroid carcinoma (MTC) or MEN2","Known serious hypersensitivity to the medication"],"specialPopulations":{"Pregnancy":"Blood Pressure Management in Pregnancy\n\nVersions - Standard Desktop\n- Mobile Web\n- Iphone/Ipad App\n\n- See Also\n- Page Contents - Gestational Hypertension\n- Hypertensive Disorders of Pregnancy - Delivery Indications in PIH\n- Mild PIH Management\n- Severe PIH Management - PIH Seizure Prophylaxis\n- HELLP Syndrome - Page Contents...\n\nIndications\n\n1. Blood Pressure exceeds 160/110 mmHg (Severe Preeclampsia) for more than 15 minutes\n\nIII. Protocol: Initial program (Titrate to BP <160/110 mmHg)\n\nPrecautions   ...    2. See Severe PIH Management for other important Severe PIH Interventions (e.g. Magnesium Sulfate) Labetolol (Normodyne)\n\nSafe and offers benefits over Hydralazine\n1. Lower Incidence of maternal Hypotension\n2. Lower Incidence of ceserean delivery   ...    1. Start at Labetolol 20 mg IV for first dose as above\n2. If insufficient effect after 10 min: 40 mg IV   ...    1. Labetalol 100 mg orally twice to three times daily and titrate   ...    Contraindications\n\n1. Avoid in Asthma\n2. Avoid in Congestive Heart Failure Nifedipine XL (Procardia XL)\n\nStart: 10 mg PO every 20-30 minutes prn (up to 3 doses)   ...    Hydralazine(Apresazide)\n\nWas considered drug of choice due to 30 years of PIH use\n1. Now considered third line (after Labetolol and Nifedipine) due to adverse effects\n\nAdverse effects\n1. Fetal Tachycardia\n2. Maternal Headache or Palpitation s   ...    Second-Line, Refractory Severe Hypertension(not recommended by ACOG for first-line use)   ...    2. [(2017) Obstet Gynecol 129(4):e90-5 +PMID: 28333820 [PubMed]]   ...    IV. Management: Maintanence medications (titrate to keep BP <160/110)\n\n1. Methyldopa 250-500 mg orally 2-4 times daily\n2. Labetalol 100-400 mg orally twice daily\n3. Hydralazine 10-50 mg orally four times daily\n4. Nifedipine ER or XL 30-90 mg daily\n\nV. Management: Postpartum\n\nAntihypertensive indications\n1. Postpartum for BP >150/100 mmHg on at least 2 readings 4 hours apart   ...    Pregnancy Related Hypertension is a significant risk for Cerebrovascular Accident Manage Blood Pressure appropriately with goal BP <160/110 mmHg\n\n1. CVA in Severe Preeclampsia typically occurs with BP >160/110 mmHg\n2. [Martin (2005) Obstet Gynecol 105(2): 246-54 [PubMed]] Other Antihypertensive indications in pregnancy vary by condition\n\n1. Chronic Hypertension is treated at BP >140/90 mmHg\n2. Postpartum Hypertension is treated at BP >150/100 mmHg\n3. Gestational Hypertension is not treated unless >160/110 mmHg (gestationa Hypertension with   ...    Avoid contraindicated Antihypertensive s\n\nAvoid Atenolol(due to IUGR risk)   ...    Avoid Thiazide Diuretic s (maternal fluid depletion, Hypokalemia)\n1. Although Thiazide Diuretic s may be continued if on chronically prior to pregnancy\n\nVII. Complications: Severe Maternal Hypertension\n\n1. Acute Co","Geriatric use":"No specific guidance for geriatric use","Paediatric use":"No specific guidance for paediatric use","Renal impairment":"No specific guidance for renal impairment","Hepatic impairment":"No specific guidance for hepatic impairment"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=placebp","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:57:16.009555+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:57:28.713425+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:21.485604+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:57:16.081793+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=placebp","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:21.682530+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Placebp is a placebo marketed by Pfizer, primarily indicated for use in clinical trials for Major Depressive Disorder. Its key strength lies in serving as a reliable control in clinical trials, essential for establishing the efficacy of new treatments. The primary risk is the availability of established alternatives such as Sertraline and Lithium, which may limit the demand for placebo-controlled trials.","brandName":"Placebp","ecosystem":[],"isGeneric":true,"mechanism":{"target":"None","novelty":"Not applicable","modality":"Inert Substance","drugClass":"Placebo","explanation":"","oneSentence":"","technicalDetail":"Placebos are typically formulated to mimic the appearance and administration route of the active drug being tested, ensuring that participants in the control group experience the same sensory and procedural aspects of the treatment."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:43.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","launchDate":"Not applicable","annualCostUS":"80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Not applicable","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=placebp","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=placebp","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:57:28.713523+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lithium","company":"Various","advantage":"Lithium is often used as an alternative to placebo-controlled trials in treating bipolar disorder, as it has been shown to be effective in managing symptoms."},{"name":"Sertraline","company":"Pfizer","advantage":"Sertraline is a commonly used antidepressant that can be used as an alternative to placebo-controlled trials in treating depression, as it has been shown to be effective in managing symptoms."},{"name":"Risperidone","company":"Janssen Pharmaceuticals","advantage":"Risperidone is an antipsychotic medication that can be used as an alternative to placebo-controlled trials in treating schizophrenia, as it has been shown to be effective in managing symptoms."},{"name":"Valproate","company":"Various","advantage":"Valproate is an anticonvulsant medication that can be used as an alternative to placebo-controlled trials in treating bipolar disorder, as it has been shown to be effective in managing symptoms."}],"genericName":"placebp","indications":{"approved":[{"name":"Major Depressive Disorder","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06325657","phase":"PHASE3","title":"A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-12","conditions":"Respiratory Syncytial Virus","enrollment":648},{"nctId":"NCT03864445","phase":"PHASE2","title":"Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-04-29","conditions":"Hyperphosphatemia","enrollment":47},{"nctId":"NCT01261403","phase":"PHASE2","title":"Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Celularity Incorporated","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT04094597","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Oral Bovine Lactoferrin","status":"COMPLETED","sponsor":"Cairo University","startDate":"2018-01-01","conditions":"Neonatal SEPSIS","enrollment":200},{"nctId":"NCT00444574","phase":"PHASE3","title":"Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2004-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":282}],"_emaApprovals":[{"date":"","name":"Placebp","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Inert Substance","firstApprovalDate":"Not applicable","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:57:28.713523+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}